Intellia Therapeutics Stock Analysis
Intellia Therapeutics is undervalued with Real Value of 17.31 and Hype Value of 11.75. The main objective of Intellia Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Intellia Therapeutics is worth, separate from its market price. There are two main types of Intellia Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Intellia Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Intellia Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. Intellia Stock Analysis Notes
About 88.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.78. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Intellia Therapeutics recorded a loss per share of 4.69. The entity had not issued any dividends in recent years. Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Intellia Thera operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 485 people. To find out more about Intellia Therapeutics contact John MD at 857 285 6200 or learn more at https://www.intelliatx.com.Intellia Therapeutics Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Intellia Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Intellia Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Intellia Therapeutics is not yet fully synchronised with the market data | |
| Intellia Therapeutics has some characteristics of a very speculative penny stock | |
| Intellia Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 57.88 M. Net Loss for the year was (519.02 M) with loss before overhead, payroll, taxes, and interest of (387.25 M). | |
| Intellia Therapeutics currently holds about 874.28 M in cash with (348.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 11.5. | |
| Over 88.0% of the company shares are owned by institutional investors |
Intellia Therapeutics Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Intellia Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Intellia Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.28 B.Intellia Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Intellia Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Intellia Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Intellia Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Intellia Therapeutics Outstanding Bonds
Intellia Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Intellia Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Intellia bonds can be classified according to their maturity, which is the date when Intellia Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Intellia Therapeutics Technical and Predictive Indicators
| Risk Adjusted Performance | 0.1103 | |||
| Market Risk Adjusted Performance | 0.324 | |||
| Mean Deviation | 3.22 | |||
| Semi Deviation | 3.13 | |||
| Downside Deviation | 3.72 | |||
| Coefficient Of Variation | 671.17 | |||
| Standard Deviation | 4.15 | |||
| Variance | 17.24 | |||
| Information Ratio | 0.1209 | |||
| Jensen Alpha | 0.4022 | |||
| Total Risk Alpha | (0.04) | |||
| Sortino Ratio | 0.1349 | |||
| Treynor Ratio | 0.314 | |||
| Maximum Drawdown | 19.34 | |||
| Value At Risk | (5.10) | |||
| Potential Upside | 8.17 | |||
| Downside Variance | 13.86 | |||
| Semi Variance | 9.78 | |||
| Expected Short fall | (3.57) | |||
| Skewness | 0.1421 | |||
| Kurtosis | (0.16) |
| Risk Adjusted Performance | 0.1103 | |||
| Market Risk Adjusted Performance | 0.324 | |||
| Mean Deviation | 3.22 | |||
| Semi Deviation | 3.13 | |||
| Downside Deviation | 3.72 | |||
| Coefficient Of Variation | 671.17 | |||
| Standard Deviation | 4.15 | |||
| Variance | 17.24 | |||
| Information Ratio | 0.1209 | |||
| Jensen Alpha | 0.4022 | |||
| Total Risk Alpha | (0.04) | |||
| Sortino Ratio | 0.1349 | |||
| Treynor Ratio | 0.314 | |||
| Maximum Drawdown | 19.34 | |||
| Value At Risk | (5.10) | |||
| Potential Upside | 8.17 | |||
| Downside Variance | 13.86 | |||
| Semi Variance | 9.78 | |||
| Expected Short fall | (3.57) | |||
| Skewness | 0.1421 | |||
| Kurtosis | (0.16) |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Intellia Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Efficient Frontier Now
Efficient FrontierPlot and analyze your portfolio and positions against risk-return landscape of the market. |
| All Next | Launch Module |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Other Tools for Intellia Stock
When running Intellia Therapeutics' price analysis, check to measure Intellia Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intellia Therapeutics is operating at the current time. Most of Intellia Therapeutics' value examination focuses on studying past and present price action to predict the probability of Intellia Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intellia Therapeutics' price. Additionally, you may evaluate how the addition of Intellia Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |